期刊
INTERNATIONAL JOURNAL OF CANCER
卷 124, 期 1, 页码 157-166出版社
WILEY
DOI: 10.1002/ijc.23864
关键词
simulation model; cost-effectiveness; Helicobacter pylori; gastric cancer
类别
资金
- National Cancer Institute [R25-CA92203]
- NATIONAL CANCER INSTITUTE [R25CA092203] Funding Source: NIH RePORTER
Gastric cancer is the second leading cause or cancer-related deaths worldwide. Treatment for Helicobacter pylori infection, the leading causal risk factor, can reduce disease progression, but the long-term impact on cancer incidence is uncertain, Using the best available data, we estimated the potential health benefits and economic consequences associated with H. pylori screening in a high-risk region of China. An empirically calibrated model of gastric cancer was used to project reduction in lifetime cancer risk, life-expectancy and costs associated with (i) single lifetime screening (age 20, 30 or 40); (ii) single lifetime screening followed by rescreening individuals with negative results and (iii) universal treatment for H. pylori (age 20, 30 or 40). Data were from the published literature and national ant] international databases. Screening and treatment for H. pylori at age 20 reduced the mean lifetime cancer risk by 14.5% (men) to 26.6% (women) anti cost less than $1,500 per year of life saved (YLS) compared to no screening. Rescreening individuals with negative results anti targeting older ages was less cost-effective. Universal treatment prevented an additional 1.5% to 2.3% of risk reduction, but incremental cost-effectiveness ratios exceeded $2,500 per YLS. Screening young adults for H. pylori could prevent one in every 4 to 6 cases of gastric cancer in China and would he considered cost-effective using the GDP per capita threshold. These results illustrate the potential promise or a gastric cancer screening program anti provide rationale for urgent clinical studies to move the prevention agenda forward. (C) 2008 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据